ribupatide

all catalysts(0)

nothing on the calendar yet

News(4)

• Chutes & Ladders—Former Legend CEO lands at K2
  Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…
  fiercebiotech · 4d ago
• Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
  Jennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…
  biospace · 24d ago
• Kailera says obesity pill succeeds in late-stage trial in China
  The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
  biopharma_dive · 1mo ago
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
  biopharma_dive · 3mo ago